Literature DB >> 12775358

Interleukin (IL)-1 gene polymorphisms: relevance of disease severity associated alleles with IL-1beta and IL-1ra production in multiple sclerosis.

Hans M Schrijver1, Jaco van As, J Bart A Crusius, Christien D Dijkstra, Bernard M J Uitdehaag.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is an autoimmune disorder, with a considerable genetic influence on susceptibility and disease course. Cytokines play an important role in MS pathophysiology, and genes encoding various cytokines are logical candidates to assess possible associations with MS susceptibility and disease course. We previously reported an association of a combination of polymorphisms in the interleukin (IL)-1B and IL-1 receptor antagonist (IL-1RN) genes (i.e. IL-1RN allele 2+/IL-1B(+3959)allele 2-) with disease severity in MS. Extending this observation, we investigated whether IL-1beta and IL-1ra production differed depending on carriership of this gene combination.
METHODS: Twenty MS patients and 20 controls were selected based upon carriership of the specific combination. In whole blood, in vitro IL-1beta and IL-1ra production was determined by enzyme-linked immunosorbent-assay after 6 and 24 h of stimulation with lipopolysaccharide.
RESULTS: Carriers of the specific combination produced more IL-1ra, especially in MS patients, although not significantly. IL-1ra production was significantly higher in individuals homozygous for IL-1RN allele 2. In patients, Il-1ra production was higher and IL-1beta production lower compared with controls. In primary progressive patients, the IL-1beta /IL-1ra ratio was significantly lower than in relapsing-remitting patients.
CONCLUSION: Our results suggest higher in vitro IL-1ra production in carriers of IL-1RN allele 2, with an indication of an allelic dose-effect relationship.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775358      PMCID: PMC1781595          DOI: 10.1080/0962933031000097691

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  20 in total

1.  Comparison of cytokine production in cultures of whole human blood and purified mononuclear cells.

Authors:  P Yaqoob; E A Newsholme; P C Calder
Journal:  Cytokine       Date:  1999-08       Impact factor: 3.861

2.  Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat.

Authors:  J K Tarlow; A I Blakemore; A Lennard; R Solari; H N Hughes; A Steinkasserer; G W Duff
Journal:  Hum Genet       Date:  1993-05       Impact factor: 4.132

3.  Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis.

Authors:  Brigit A de Jong; Tom W J Huizinga; Eduard L E M Bollen; Bernard M J Uitdehaag; Gerlof P Th Bosma; Mark A van Buchem; Edmond J Remarque; Alexandra C S Burgmans; Nynke F Kalkers; Chris H Polman; Rudi G J Westendorp
Journal:  J Neuroimmunol       Date:  2002-05       Impact factor: 3.478

4.  Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity.

Authors:  C L A Mann; M B Davies; V L Stevenson; S M Leary; M D Boggild; C Ko Ko; P W Jones; A A Fryer; R C Strange; A J Thompson; C P Hawkins
Journal:  J Neuroimmunol       Date:  2002-08       Impact factor: 3.478

5.  A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro.

Authors:  F Pociot; J Mølvig; L Wogensen; H Worsaae; J Nerup
Journal:  Eur J Clin Invest       Date:  1992-06       Impact factor: 4.686

6.  Monokine antagonism is reduced in patients with IDDM.

Authors:  T Mandrup-Poulsen; F Pociot; J Mølvig; L Shapiro; P Nilsson; T Emdal; M Røder; L L Kjems; C A Dinarello; J Nerup
Journal:  Diabetes       Date:  1994-10       Impact factor: 9.461

7.  Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism.

Authors:  V A Danis; M Millington; V J Hyland; D Grennan
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

8.  Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus.

Authors:  A I Blakemore; J K Tarlow; M J Cork; C Gordon; P Emery; G W Duff
Journal:  Arthritis Rheum       Date:  1994-09

9.  Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis.

Authors:  R Feakes; S Sawcer; S Broadley; F Coraddu; R Roxburgh; J Gray; D Clayton; A Compston
Journal:  J Neuroimmunol       Date:  2000-06-01       Impact factor: 3.478

Review 10.  Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.

Authors:  W P Arend
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

View more
  8 in total

1.  IL1RN*2 allele of IL-1receptor antagonist VNTR polymorphism is associated with susceptibility to ankylosing [corrected] spondylitis in Indian patients.

Authors:  Sumeet Agrawal; Rajni Srivastava; Banwari Sharma; Sapan Pandya; Ramnath Misra; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2007-09-27       Impact factor: 2.980

2.  Association of the -31C/T functional polymorphism in the interleukin-1beta gene with the intractability of Graves' disease and the proportion of T helper type 17 cells.

Authors:  F Hayashi; M Watanabe; T Nanba; N Inoue; T Akamizu; Y Iwatani
Journal:  Clin Exp Immunol       Date:  2009-09-30       Impact factor: 4.330

Review 3.  Interplay of cytokines in preterm birth.

Authors:  Monika Pandey; Mradula Chauhan; Shally Awasthi
Journal:  Indian J Med Res       Date:  2017-09       Impact factor: 2.375

4.  The Allele 2 of the VNTR Polymorphism in the Gene That Encodes a Natural Inhibitor of IL-1β, IL-1RA Is Favorably Associated With Chronic Otitis Media.

Authors:  Maja Živković; Ivana Kolić; Snežana Jesić; Ana Jotić; Aleksandra Stanković
Journal:  Clin Exp Otorhinolaryngol       Date:  2018-02-14       Impact factor: 3.372

5.  IL-37 exerts therapeutic effects in experimental autoimmune encephalomyelitis through the receptor complex IL-1R5/IL-1R8.

Authors:  Alba Sánchez-Fernández; Stephanie Zandee; Jesús Amo-Aparicio; Marc Charabati; Alexandre Prat; Cecilia Garlanda; Elan Z Eisenmesser; Charles A Dinarello; Rubèn López-Vales
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 6.  Toward Overcoming Treatment Failure in Rheumatoid Arthritis.

Authors:  Zhuqian Wang; Jie Huang; Duoli Xie; Dongyi He; Aiping Lu; Chao Liang
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

7.  Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome.

Authors:  Reham A Ammar; Ahmed F Mohamed; Mohamed M Kamal; Marwa M Safar; Noha F Abdelkader
Journal:  Inflammopharmacology       Date:  2022-04-01       Impact factor: 5.093

8.  Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis.

Authors:  Alba Sánchez-Fernández; Stephanie Zandee; Mauricio Mastrogiovanni; Marc Charabati; Homero Rubbo; Alexandre Prat; Rubèn López-Vales
Journal:  J Neuroinflammation       Date:  2022-02-02       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.